4 assets in Mixed Testicular Germ Cell Cancer

Therapeutic assets addressing Mixed Testicular Germ Cell Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Carboplatin Mixed Testicular Germ Cell Cancer	Children's Oncology Group	P3	BB (66)
Bleomycin Mixed Testicular Germ Cell Cancer	Children's Oncology Group	P3	B (60)
Cis-Diamminedichloroplatinum Ii Mixed Testicular Germ Cell Cancer	Children's Oncology Group	P3	B (60)
Etoposide Mixed Testicular Germ Cell Cancer	Children's Oncology Group	P3	B (60)